Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients

Schizophrenia Research

Volumn 147, Issue 1, 2013, Pages 24-31

  Rao, Jagadeesh Sridhara ^a   Kim, Hyung Wook ^a   Harry, Gaylia Jean ^b   Rapoport, Stanley Isaac ^a   Reese, Edmund Arthur ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Arachidonic acid cascade; Brain; Cytokines; Drebrin; Inflammation; Schizophrenia; Synapse; Synaptophysin

Indexed keywords

ARACHIDONIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; CLOZAPINE; DREBRIN; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; PROTEIN C FOS; RISPERIDONE; SYNAPSE RECEPTOR; SYNAPTOPHYSIN; TRAZODONE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ADULT; AGED; ARTICLE; AUTOPSY; CANCER GROWTH; CAUSE OF DEATH; CELL STRUCTURE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOSOL; EXCITOTOXICITY; FEMALE; FRONTAL CORTEX; HUMAN; IMMUNOHISTOCHEMISTRY; MACROGLIA; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SCHIZOPHRENIA; WESTERN BLOTTING;

ADULT; AGED; ANALYSIS OF VARIANCE; ARACHIDONIC ACID; CYTOKINES; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; HLA-DR ANTIGENS; HUMANS; MALE; MICROGLIA; MIDDLE AGED; NERVE TISSUE PROTEINS; NITRIC OXIDE SYNTHASE TYPE II; POSTMORTEM CHANGES; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 84877123887     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.02.017     Document Type: Article

References (71)

1. Acarin L., Peluffo H., Gonzalez B., Castellano B. Expression of inducible nitric oxide synthase and cyclooxygenase-2 after excitotoxic damage to the immature rat brain. J. Neurosci. Res. 2002, 68(6):745-754.
2. Aoki C., Sekino Y., Hanamura K., Fujisawa S., Mahadomrongkul V., Ren Y., Shirao T. Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses. J. Comp. Neurol. 2005, 483(4):383-402.
3. Barbosa N.R., Junqueira R.M., Vallada H.P., Gattaz W.F. Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2007, 257(6):340-343.
4. Basselin M., Ramadan E., Chen M., Rapoport S.I. Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites. Neurochem. Res. 2011, 36(1):139-145.
5. Beasley C.L., Dwork A.J., Rosoklija G., Mann J.J., Mancevski B., Jakovski Z., Davceva N., Tait A.R., Straus S.K., Honer W.G. Metabolic abnormalities in fronto-striatal-thalamic white matter tracts in schizophrenia. Schizophr. Res. 2009, 109(1-3):159-166.
6. Bilder R.M., Howe A., Novak N., Sabb F.W., Parker D.S. The genetics of cognitive impairment in schizophrenia: a phenomic perspective. Trends Cogn. Sci. 2011, 15(9):428-435.
7. Blais V., Rivest S. Inhibitory action of nitric oxide on circulating tumor necrosis factor-induced NF-kappaB activity and COX-2 transcription in the endothelium of the brain capillaries. J. Neuropathol. Exp. Neurol. 2001, 60(9):893-905.
8. Censits D.M., Ragland J.D., Gur R.C., Gur R.E. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr. Res. 1997, 24(3):289-298.
9. Chen K.H., Reese E.A., Kim H.W., Rapoport S.I., Rao J.S. Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J. Alzheimers Dis. 2011, 26(4):755-766.
10. Cheon Y., Park J.Y., Modi H.R., Kim H.W., Lee H.J., Chang L., Rao J.S., Rapoport S.I. Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E(2) concentration in rat brain. J. Neurochem. 2011, 119(2):364-376.
11. Crespo-Facorro B., Rodriguez-Sanchez J.M., Perez-Iglesias R., Mata I., Ayesa R., Ramirez-Bonilla M., Martinez-Garcia O., Vazquez-Barquero J.L. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J. Clin. Psychiatry 2009, 70(5):717-729.
12. de Castro-Manglano P., Mechelli A., Soutullo C., Gimenez-Amaya J., Ortuno F., McGuire P. Longitudinal changes in brain structure following the first episode of psychosis. Psychiatry Res. 2011, 191(3):166-173.
13. Drexhage R.C., Padmos R.C., de Wit H., Versnel M.A., Hooijkaas H., van der Lely A.J., van Beveren N., deRijk R.H., Cohen D. Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?. Schizophr. Res. 2008, 102(1-3):352-355.
14. Eckert G.P., Schaeffer E.L., Schmitt A., Maras A., Gattaz W.F. Increased brain membrane fluidity in schizophrenia. Pharmacopsychiatry 2011, 44(4):161-162.
15. Esposito G., Giovacchini G., Liow J.S., Bhattacharjee A.K., Greenstein D., Schapiro M., Hallett M., Herscovitch P., Eckelman W.C., Carson R.E., Rapoport S.I. Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J. Nucl. Med. 2008, 49(9):1414-1421.
16. Everall I.P., Heaton R.K., Marcotte T.D., Ellis R.J., McCutchan J.A., Atkinson J.H., Grant I., Mallory M., Masliah E. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC group. HIV Neurobehavioral Research Center. Brain Pathol. 1999, 9(2):209-217.
17. Fang K.M., Chang W.L., Wang S.M., Su M.J., Wu M.L. Arachidonic acid induces both Na+ and Ca2+ entry resulting in apoptosis. J. Neurochem. 2008, 104(5):1177-1189.
18. Farooqui A.A., Yi Ong W., Lu X.R., Halliwell B., Horrocks L.A. Neurochemical consequences of kainate-induced toxicity in brain: involvement of arachidonic acid release and prevention of toxicity by phospholipase A(2) inhibitors. Brain Res. Brain Res. Rev. 2001, 38(1-2):61-78.
19. Funk D.J., Kumar A. Antimicrobial therapy for life-threatening infections: speed is life. Crit. Care Clin. 2011, 27(1):53-76.
20. Harigaya Y., Shoji M., Shirao T., Hirai S. Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J. Neurosci. Res. 1996, 43(1):87-92.
21. Harvey P.D., Powchik P., Mohs R.C., Davidson M. Memory functions in geriatric chronic schizophrenic patients: a neuropsychological study. J. Neuropsychiatry Clin. Neurosci. 1995, 7(2):207-212.
22. Hatanpaa K., Isaacs K.R., Shirao T., Brady D.R., Rapoport S.I. Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1999, 58(6):637-643.
23. Hernandez M., Bayon Y., Sanchez Crespo M., Nieto M.L. Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2. J. Neurochem. 1999, 73(4):1641-1649.
24. Hernandez M., Fuentes L., Fernandez Aviles F.J., Crespo M.S., Nieto M.L. Secretory phospholipase A(2) elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells: potential relevance for atherogenesis. Circ. Res. 2002, 90(1):38-45.
25. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 1991, 30(8):795-805.
26. Huang S.K., Klein D.C., Korf H.W. Immunocytochemical demonstration of rod-opsin, S-antigen, and neuron-specific proteins in the human pineal gland. Cell Tissue Res. 1992, 267(3):493-498.
27. Igarashi M., Kim H.W., Chang L., Ma K., Rapoport S.I. Dietary n-6 polyunsaturated fatty acid deprivation increases docosahexaenoic acid metabolism in rat brain. J. Neurochem. 2012, 120(6):985-997.
28. Kim H.W., Rao J.S., Rapoport S.I., Igarashi M. Regulation of rat brain polyunsaturated fatty acid (PUFA) metabolism during graded dietary n-3 PUFA deprivation. Prostaglandins Leukot. Essent. Fatty Acids 2011, 85(6):361-368.
29. Kim H.W., Cheon Y., Modi H.R., Rapoport S.I., Rao J.S. Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain. Psychopharmacology (Berl) 2012, 222(4):663-674.
30. Kim, H.W., Rapoport, S.I., Rao, J.S., 2010. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol. Dis. 37 (3) 596-603.
31. Kojima N., Kato Y., Shirao T., Obata K. Nucleotide sequences of two embryonic drebrins, developmentally regulated brain proteins, and developmental change in their mRNAs. Brain Res. 1988, 464(3):207-215.
32. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010, 71(5):520-527.
33. Laflamme N., Lacroix S., Rivest S. An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J. Neurosci. 1999, 19(24):10923-10930.
34. Leuba G., Walzer C., Vernay A., Carnal B., Kraftsik R., Piotton F., Marin P., Bouras C., Savioz A. Postsynaptic density protein PSD-95 expression in Alzheimer's disease and okadaic acid induced neuritic retraction. Neurobiol. Dis. 2008, 30(3):408-419.
35. Licinio J., Seibyl J.P., Altemus M., Charney D.S., Krystal J.H. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry 1993, 150(9):1408-1410.
36. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408.
37. Martinez-Gras I., Perez-Nievas B.G., Garcia-Bueno B., Madrigal J.L., Andres-Esteban E., Rodriguez-Jimenez R., Hoenicka J., Palomo T., Rubio G., Leza J.C. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr. Res. 2011, 128(1-3):15-22.
38. Masliah E., Heaton R.K., Marcotte T.D., Ellis R.J., Wiley C.A., Mallory M., Achim C.L., McCutchan J.A., Nelson J.A., Atkinson J.H., Grant I. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC group. The HIV Neurobehavioral Research Center. Ann. Neurol. 1997, 42(6):963-972.
39. Mathe A.A., Eberhard G., Saaf J., Wetterberg L. Plasma prostaglandin E2 metabolite - measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2 - in twins with schizophrenic disorder. Biol. Psychiatry 1986, 21(11):1024-1030.
40. McCarthy M., Vidaurre I., Geffin R. Maturing neurons are selectively sensitive to human immunodeficiency virus type 1 exposure in differentiating human neuroepithelial progenitor cell cultures. J. Neurovirol. 2006, 12(5):333-348.
41. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.G., Richtand N.M., Stanford K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr. Res. 2007, 91(1-3):37-50.
42. Modi H.R., Taha A.Y., Kim H.W., Chang L., Rapoport S.I., Cheon Y. Chronic clozapine reduces rat brain arachidonic acid metabolism by reducing plasma arachidonic acid availability. J. Neurochem. 2013, 124(3):376-387.
43. Moolwaney A.S., Igwe O.J. Regulation of the cyclooxygenase-2 system by interleukin-1beta through mitogen-activated protein kinase signaling pathways: a comparative study of human neuroglioma and neuroblastoma cells. Brain Res. Mol. Brain Res. 2005, 137(1-2):202-212.
44. Muller N., Schwarz M.J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl. 2):97-106.
45. Nishino S., Mignot E., Benson K.L., Zarcone V.P. Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 1998, 78(3):141-150.
46. Noponen M., Sanfilipo M., Samanich K., Ryer H., Ko G., Angrist B., Wolkin A., Duncan E., Rotrosen J. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry 1993, 34(9):641-649.
47. Okuda S., Saito H., Katsuki H. Arachidonic acid: toxic and trophic effects on cultured hippocampal neurons. Neuroscience 1994, 63(3):691-699.
48. Pantelis C., Brewer W. Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia. Schizophr. Res. 1995, 17(1):35-45.
49. Peet M. Nutrition and schizophrenia: an epidemiological and clinical perspective. Nutr. Health 2003, 17(3):211-219.
50. Price G., Cercignani M., Chu E.M., Barnes T.R., Barker G.J., Joyce E.M., Ron M.A. Brain pathology in first-episode psychosis: magnetization transfer imaging provides additional information to MRI measurements of volume loss. Neuroimage. 2010, 49(1):185-192.
51. Rao J.S., Ertley R.N., Rapoport S.I., Bazinet R.P., Lee H.J. Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. J. Neurochem. 2007, 102(6):1918-1927.
52. Rao J.S., Harry G.J., Rapoport S.I., Kim H.W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010, 15(4):384-392.
53. Rao J.S., Kim H.W., Kellom M., Greenstein D., Chen M., Kraft A.D., Harry G.J., Rapoport S.I., Basselin M. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats. J. Neuroinflammation 2011, 8:101.
54. Rao J.S., Rapoport S.I., Kim H.-W. Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimer's disease brain. Transl. Psychiatry 2011, 2011-2027.
55. Rao J.S., Kellom M., Kim H.W., Rapoport S.I., Reese E.A. Neuroinflammation and synaptic loss. Neurochem Res. 2012, 37(5):903-910.
56. Rao J.S., Kellom M., Reese E.A., Rapoport S.I., Kim H.W. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J. Affect. Disord. 2012, 136(1-2):63-71.
57. Rogers A., Schmuck G., Scholz G., Griffiths R., Meredith C., Schousboe A., Campiani G., Williams D.C. Improvements in an in-vitro assay for excitotoxicity by measurement of early gene (c-Fos mRNA) levels. Arch. Toxicol. 2005, 79(3):129-139.
58. Rosenberger T.A., Villacreses N.E., Hovda J.T., Bosetti F., Weerasinghe G., Wine R.N., Harry G.J., Rapoport S.I. Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide. J. Neurochem. 2004, 88(5):1168-1178.
59. Sanchez-Mejia R.O., Newman J.W., Toh S., Yu G.Q., Zhou Y., Halabisky B., Cisse M., Scearce-Levie K., Cheng I.H., Gan L., Palop J.J., Bonventre J.V., Mucke L. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci. 2008, 11(11):1311-1318.
60. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., Bernstein H.G., Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008, 42(2):151-157.
61. Sun G.Y., Xu J., Jensen M.D., Simonyi A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res. 2004, 45(2):205-213.
62. Taha A.Y., Cheon Y., Kaizong M., Rapoport S.I., Rao J.S. Altered fatty acid concentrations in prefrontal cortex of schizophrenic patients. J. Psychiatr. Res. 2013, 47(5):636-643.
63. Taylor D.L., Jones F., Kubota E.S., Pocock J.M. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J. Neurosci. 2005, 25(11):2952-2964.
64. Terry-Lorenzo R.T., Inoue M., Connor J.H., Haystead T.A., Armbruster B.N., Gupta R.P., Oliver C.J., Shenolikar S. Neurofilament-L is a protein phosphatase-1-binding protein associated with neuronal plasma membrane and post-synaptic density. J. Biol. Chem. 2000, 275(4):2439-2446.
65. Townsend L.A., Malla A.K., Norman R.M. Cognitive functioning in stabilized first-episode psychosis patients. Psychiatry Res. 2001, 104(2):119-131.
66. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A.D., Cahn W., Lammertsma A.A., Kahn R.S. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64(9):820-822.
67. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry 1988, 45(7):609-615.
68. Williams J.R., Leaver H.A., Ironside J.W., Miller E.P., Whittle I.R., Gregor A. Apoptosis in human primary brain tumours: actions of arachidonic acid. Prostaglandins Leukot. Essent. Fatty Acids 1998, 58(3):193-200.
69. Yagami T. Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia. Curr. Neuropharmacol. 2006, 4(1):87-100.
70. Yagami T., Ueda K., Asakura K., Hata S., Kuroda T., Sakaeda T., Takasu N., Tanaka K., Gemba T., Hori Y. Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol. Pharmacol. 2002, 61(1):114-126.
71. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 2000, 42(1):7-17.